Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current Assets
Cash and cash equivalents	$ 18,650	$ 28,918
Prepaid expenses and other current assets	1,193	593
Total Current Assets	19,843	29,511
Property and equipment, net	425	607
Right of Use Asset	451	0
Deposits and other assets	23	23
Total Assets	20,742	30,141
Current Liabilities:
Accounts payable	2,452	1,034
Accrued expenses	2,321	919
Accrued employee benefits	619	1,332
Deferred rent	0	99
Lease liability	241	0
Total Current Liabilities	5,633	3,384
Long term deferred rent	0	302
Lease liability - Long term	539	0
Total Liabilities	6,172	3,686
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 120,000 issued and outstanding	12,481	12,296
Stockholders' Equity:
Common stock, $0.001 par value; 200,000,000 shares authorized, 16,808,758, issued and 16,806,430 outstanding and 15,484,411, issued and 15,482,083 outstanding	17	15
Additional paid-in capital	232,485	230,754
Accumulated deficit	(232,394)	(219,461)
Total Synthetic Biologics, Inc. and Subsidiaries Equity	4,930	17,068
Non-controlling interest	(2,841)	(2,909)
Total Stockholders' Equity	2,089	14,159
Total Liabilities and Stockholders' Equity	20,742	30,141
Series B Preferred Stock [Member]
Stockholders' Equity:
Series B Convertible Preferred stock, $1,000 par value; 10,000,000 shares authorized, 7,638 issued and outstanding and 9,161 issued and outstanding	4,822	5,760
Total Stockholders' Equity	$ 4,822	$ 5,760